Volume 19, Number 7—July 2013
Research
Pneumococcal Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999–20111
, Kristopher P. Heilmann, Cassie L. Dohrn, Fathollah Riahi, Daniel J. Diekema, and Gary V. Doern
Table 3
Serotype distribution of Streptococcus pneumoniae noninvasive and invasive isolates, United States, 1999–2011*
| Serotype | No. (%) isolates |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Noninvasive |
Invasive |
||||||||
| Before PCV7, 1999–2000 | Post-PCV7, 2004–2005 | Post-PCV7, 2008–2009 | Post-PCV13, 2010–2011 | Before PCV7, 1999–2000 | Post-PCV7, 2004–2005 | Post-PCV7, 2008–2009 | Post-PCV13, 2010–2011 | ||
| PCV7 | |||||||||
| 4† | 20 (1.9) | 11 (0.9) | 5 (0.4) | 2 (0.2) | 49 (10.2) | 23 (5.3) | 2 (0.4) | 4 (0.9) | |
| 6B† | 104 (10.1) | 25 (2.1) | 5 (0.4) | 7 (0.5) | 53 (11.0) | 7 (1.6) | 3 (0.6) | 4 (0.9) | |
| 9V† | 47 (4.6) | 12 (1.0) | 5 (0.4) | 0 | 30 (6.3) | 9 (2.1) | 0 | 1 (0.2) | |
| 14† | 69 (6.7) | 9 (0.7) | 5 (0.4) | 0 | 82 (17.1) | 4 (0.9) | 2 (0.4) | 1 (0.2) | |
| 18C† | 25 (2.4) | 6 (0.5) | 0 | 2 (0.2) | 26 (5.4) | 4 (0.9) | 2 (0.4) | 1 (0.2) | |
| 19F† | 144 (14.0) | 95 (7.8) | 55 (3.8) | 41 (3.1) | 37 (7.7) | 21 (4.8) | 6 (1.2) | 6 (1.4) | |
| 23F† | 105 (10.2) | 33 (2.7) | 4 (0.3) | 3 (0.2) | 30 (6.3) | 7 (1.6) | 1 (0.2) | 0 | |
| Total | 514 (50.1) | 191 (15.8) | 79 (5.5) | 55 (4.2) | 307 (64.0) | 75 (17.2) | 16 (3.2) | 17 (3.8) | |
| Additional serotypes in PCV13 | |||||||||
| 1† | 9 (0.9) | 6 (0.5) | 4 (0.3) | 0 | 8 (1.7) | 6 (1.4) | 6 (1.2) | 2 (0.5) | |
| 3† | 108 (10.5) | 145 (12.0) | 126 (8.7) | 121 (9.3) | 19 (4.0) | 39 (8.9) | 39 (7.7) | 42 (9.5) | |
| 5† | 0 | 2 (0.2) | 0 | 1 (0.1) | 0 | 0 | 1 (0.2) | 0 | |
| 6A | 56 (5.5) | 53 (4.4) | 21 (1.5) | 4 (0.3) | 31 (6.5) | 25 (5.7) | 5 (1.0) | 3 (0.7) | |
| 7F† | 10 (1.0) | 11 (0.9) | 38 (2.6) | 31 (2.4) | 11 (2.3) | 18 (4.1) | 75 (14.9) | 55 (12.4) | |
| 19A† | 24 (2.3) | 163 (13.5) | 330 (22.9) | 269 (20.6) | 9 (1.9) | 76 (17.4) | 104 (20.6) | 81 (18.2) | |
| Total | 207 (20.2) | 380 (31.4) | 519 (36.0) | 426 (32.6) | 78 (16.3) | 164 (37.6) | 230 (45.6) | 183 (41.2) | |
| PCV related | |||||||||
| 6C | 10 (1.0) | 30 (2.5) | 104 (7.2) | 113 (8.7) | 2 (0.4) | 7 (1.6) | 37 (7.3) | 35 (7.9) | |
| 9N | 14 (1.4) | 12 (1.0) | 22 (1.5) | 20 (1.5) | 5 (1.3) | 2 (0.5) | 9 (1.8) | 14 (3.2) | |
| 23A | 10 (1.0) | 37 (3.1) | 65 (4.5) | 58 (4.4) | 0 | 10 (2.3) | 21 (4.2) | 23 (5.2) | |
| 23B | 2 (0.2) | 22 (1.8) | 50 (3.5) | 36 (2.8) | 0 | 3 (0.7) | 8 (1.6) | 8 (1.8) | |
| Other | 12 (1.2)‡ | 26 (2.1)§ | 13 (0.9)¶ | 23 (1.8)# | 6 (2.3)‡ | 10 (2.3)§ | 9 (1.8)¶ | 8 (1.8)# | |
| Total | 48 (4.7) | 127 (10.5) | 254 (17.6) | 250 (19.1) | 13 (2.7) | 32 (7.3) | 84 (16.7) | 88 (19.8) | |
| Non-PCV | |||||||||
| 11A† | 39 (3.8) | 89 (7.4) | 64 (4.4) | 71 (5.4) | 13 (2.7) | 12 (2.8) | 13 (2.6) | 11 (2.5) | |
| 12F | 4 (0.4) | 4 (0.3) | – | 3 (0.2) | 13 (2.7) | 25 (5.7) | 8 (1.6) | 11 (2.5) | |
| 15A | 6 (0.6) | 35 (2.9) | 67 (4.7) | 36 (2.8) | 1 (0.2) | 10 (2.3) | 11 (2.2) | 17 (3.8) | |
| 15B† | 5 (0.5) | 27 (2.2) | 35 (2.4) | 52 (4.0) | 2 (0.4) | 11 (2.5) | 4 (0.8) | 6 (1.4) | |
| 15C | 9 (0.9) | 21 (1.7) | 24 (1.7) | 36 (2.8) | 3 (0.6) | 9 (2.1) | 5 (1.0) | 7 (1.6) | |
| 16F | 11 (1.1) | 27 (2.2) | 44 (3.1) | 31 (2.4) | 6 (1.3) | 11 (2.5) | 13 (2.6) | 8 (1.8) | |
| 22F† | 19 (1.9) | 50 (4.1) | 53 (3.7) | 56 (4.3) | 17 (3.5) | 27 (6.2) | 42 (8.3) | 28 (6.3) | |
| 35B | 28 (2.7) | 68 (5.6) | 70 (4.9) | 104 (8.0) | 2 (0.4) | 5 (1.2) | 8 (1.6) | 19 (4.3) | |
| Other | 94 (9.2)** | 165 (13.6)†† | 198 (13.7)‡‡ | 144 (11.0)§§ | 19 (4.0)** | 52 (11.9)†† | 68 (13.5)‡‡ | 46 (10.4)§§ | |
| NT | 42 (4.1) | 27 (2.2) | 53 (2.4) | 42 (3.2) | 6 (1.3) | 3 (0.7) | 2 (0.4) | 3 (0.7) | |
| Total | 257 (25.0) | 513 (42.4) | 590 (40.9) | 575 (44.0) | 82 (17.1) | 165 (37.8) | 174 (34.5) | 156 (35.1) | |
| All | 1,026 | 1,211 | 1,442 | 1,306 | 480 | 436 | 504 | 444 | |
*PCV7, pneumococcal conjugate 7-valent vaccine; PCV13, pneumococcal conjugate 13-valent vaccine; NT, nontypeable; non, noninvasive; inv, invasive.
†Serotypes in 23-valent polysaccharide pneumococcal vaccine.
‡Other low prevalence serotypes (no. isolates): in 1999–2000, serotype 7C (2 non), 9A (4 non; 4 inv), 9L (2 non), 18F (1 non; 1 inv), 18B (3 non; 1 inv).
§In 2004–2005, serotype 6D (1 non), 7A (1 non), 7C (5 non; 3 inv), 9A (4 non; 1 inv), 9L (4 non; 1 inv), 18F (2 non; 2 inv), 18A (3 non), 18B (5 non), 19B (3 inv), 19C (1 non).
¶In 2008–2009, serotype 7C (9 non; 3 inv), 9A (2 non; 1 inv), 9L (1 non; 4 inv), 19B (1 inv), 19C (1 non).
#In 2010–2011, serotype 6D (1 non), 7B (1 non), 7C (15 non; 6 inv), 9A (1 non; 1 inv), 9L (4 non; 1 inv), 19B (1 non).
**In 1999–2000, serotype 8 (3 non; 4 inv); 10A (13 non, 1 inv); 11B (1 non); 13 (8 non); 16A (1 non); 17F (2 non); 20 (2 non; 1 inv); 21 (3 non; 1 inv); 25A (7 non; 2 inv); 25F ( 1 non); 28F (1 non); 28A (3 non; 1 inv); 29 (1 non; 2 inv); 31 (12 non; 1 inv); 33F (4 non; 1 inv); 33A (6 non; 1 inv); 34 (4 non); 35F (15 non; 3 inv); 35C (1 inv); 36 (1 non); 37 (1 non); 38 (2 non); 45 (2 non); 47 (1 non).
††In 2004–2005, serotype 2 (1 non), 8 (3 non; 4 inv), 10F (1 inv), 10A (17 non; 6 inv), 11D (1 non), 12B (1 non; 1 inv), 13 (3 non; 2 inv), 15F (1 non; 1 inv), 16A (2 non), 17F (7 non; 4 inv), 20 (4 non; 3 inv), 21 (6 non), 24F (1 non), 25A (2 non; 1 inv), 28F (2 inv), 28A (1 non; 1 inv), 29 (8 non), 31 (32 non; 4 inv), 33F (10 non; 6 inv), 33A (2 non; 4 inv), 34 (9 non; 2 inv), 35F (28 non; 6 inv), 35A (15 non), 38 (8 non; 4 inv), 39 (1 non), 40 (1 non), 48 (1 non).
‡‡In 2008–2009, serotype 8 (6 non; 7 inv), 10F (1 inv), 10A (23 non; 5 inv), 10B (1 inv), 11D (1 non), 13 (2 non; 1 inv), 16A (1 inv), 17F (24 non; 4 inv), 20 (7 non; 7 inv), 21 (19 non; 1 inv), 22A (1 non), 25A (5 non; 1 inv), 28A (2 non), 29 (6 non; 1 inv), 31 (27 non; 8 inv), 32F (1 inv), 33F (11 non; 12 inv), 33A (11 non; 6 inv), 33B (3 non), 34 (18 non; 5 inv), 35F (21 non; 4 inv), 35A (2 non), 35C (2 non), 37 (3 non), 38 (1 non; 2 inv), 42 (3 non).
§§In 2010–2011, serotype 8 (4 non; 6 inv), 10A (21 non; 5 inv), 13 (2 non), 17F (13 non; 2 inv), 20 (3 non; 3 inv), 21 (14 non; 1 inv), 24A (2 non), 28A (1 non), 29 (3 non), 31 (24 non; 4 inv), 33F (10 non; 6 inv), 33A (9 non; 9 inv), 34 (10 non; 5 inv), 35F (15 non; 2 inv), 38 (12 non; 3 inv), 45 (1 non).
1Presented in part at the 112th General Meeting of the American Society for Microbiology Annual Meeting, June 19, 2012, San Francisco, CA, USA (abstract no. 2986).